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Abstract
Introduction: Hepatic cytochrome P450s (CYPs) play an important role in the metabolism of plant carcinogen,
aristolochic acid I (AAI). In the present study, we employed hepatic NADPH-cytochrome P450 reductase null (HRN)
gpt delta transgenic mice to investigate the role of hepatic CYPs in the metabolism of AAI. DNA adduct formation,
gene mutation, and tumor induction in the liver and kidneys were analyzed. Pharmacokinetic analyses were
performed and tissue levels of AAI were determined.
Results: Pretreatment with β-naphthoflavone in wild type gpt delta transgenic mice (BNF-WT mice) could increase
the rate of clearance of AAI in blood and tissues, and decrease the formation of AAI-DNA adducts in kidney. In
contrast, there was reduced clearance of AAI in HRN gpt delta mice, which showed increased concentration of AAI
in tissues and increased levels of DNA adducts. The mutant frequencies of gpt gene, induced by AAI, in the kidneys
of HRN gpt delta mice were significantly higher than that in WT mice. In the tumor induction assay, after treatment
for 2 months with daily doses of 5 mg/kg AAI, mice were kept under observation for 7 months. During this period,
papillomatous changes occurred in the forestomach of both WT-AAI mice and HRN gpt delta-AAI mice. Squamous
cell carcinomas were found in the forestomach of 2 HRN gpt delta-AAI mice, which had also metastasized to other tissues.
In addition, adenomas were found in 2 of 8 HRN gpt delta-AAI mice, in the absence of squamous cell carcinomas.
Conclusion: These results indicated that the main role of hepatic CYPs is to aid in the excretion of AAI, and to protect the
target organs against AAI induced DNA adduct formation, mutagenesis, and tumorigenesis.
Keywords: Aristolochic acid I (AAI), Hepatic cytochrome P450 (CYP), gpt delta mice, DNA adduct, Gene mutation assay,
Tumorigenesis
Introduction
Aristolochic acid (AA), a naturally occurring nephro-
toxin and carcinogen, derived from Aristolochia plant
species, is associated with aristolochic acid nephropathy
(AAN) [1, 2], Balkan endemic nephropathy (BEN) [3],
and their urothelial malignancies [4]. Herbal remedies
containing species of the genus Aristolochia and the AA
mixture were classified as carcinogenic to humans
(Group 1) by the International Agency for Research on
Cancer [5].
The toxic effects of aristolochic acid I (AAI), a major
component of AA, have been well-studied. Metabolism
of AAI results in nephrotoxic and carcinogenic effects
(Fig. 1).
Demethylation of AAI to 8-OH-aristolochic acid I
(AAIa) is believed to be a detoxification reaction, where
AAIa is much less toxic and easily excreted in urine
compared with AAI [6–8]. In contrast, nitroreduction of
AAI is believed to be the major metabolic activation
pathway, which potentiates the carcinogenic effect. Re-
duction of a nitro group of AA will form reactive cyclic
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nitrenium ions, which can interact with the exocyclic
amino groups of deoxyadenosine and deoxyguanosine,
resulting in the preferential formation of purine adducts
7-(deoxyadenosin-N 6-yl) aristolactam I (dA-AAI) and
7-(deoxyguanosin-N 2-yl) aristolactam I (dG-AAI) [9].
The predominant AA-DNA adduct dA-AAI is a muta-
genic lesion resulting in A:T to T:A transversions in the
p53 gene of urothelial tumors from AAN and BEN pa-
tients, and in codon 61 of H-Ras gene from AAI-
treated rodents [10–12]. The cytochrome P450 (CYP)
superfamily plays a pivotal role in both detoxification
and activation of AAI. In vitro studies showed that AAI
is reduced, instead of oxidized, at low oxygen concen-
trations, whereas under aerobic conditions AAI is oxi-
dized to generate AAIa, suggesting the toxicity of AAI
may depend on the balance between oxidation and re-
duction [13]. Since in vitro studies are limited by the
absence of factors, that are important in vivo, such as
the route of administration, coupling to phase-II xeno-
biotic metabolizing enzymes, and tissue-specific expres-
sion of CYPs, in vivo studies could provide relevant
information on the actual process of AAI metabolism.
In our previous study, we used conditional hepatic
NADPH-cytochrome P450 reductase null mice (HRN
mice), and demonstrated that hepatic CYPs detoxify
AA through demethylation thus completing the detoxi-
fication cycle, and protecting kidneys from AA-induced
mice kidney injury [14, 15]. Others studied the role of
CYPs in AAI activation and the formation of AAI-DNA
adducts in Cyp1a1(−/−), Cyp1a2(−/−) [16], Cyp1a1/
1a2(−/−) mice [17], HRN mice [18], and humanized
hCYP1A mice [19]. Since carcinogenesis is a multistep
process, there is no single toxicological end point that
is associated with complete carcinogenic potency. Risk
assessment of a chemical should involve multistep ana-
lysis of carcinogenesis, and thus, the role of CYPs in
AAI-induced mutagenesis and carcinogenesis in vivo
still needs to be confirmed.
We previously reported the generation of an HRN gpt
delta mouse model, by crossing HRN mice with gpt delta
transgenic mice [20], which was a useful tool for investi-
gating the role of hepatic CYPs in the metabolism of
genotoxic carcinogens. In the present study, we analyzed
the formation of DNA adducts, mutant frequencies of
gpt gene as well as mutation spectrum characteristics,
tumor induction in AAI- treated HRN gpt delta mice,
combined with pharmacokinetic analysis and tissue level
detection of AAI. Among the P450 superfamily, CYP1A
Fig. 1 The balance between oxidative detoxication and reductive activation of aristolochic acid I (AAI). Detoxification of AAI by O-demethylation
to generate AAIa, and bio-activation of AAI by nitroreduction to form DNA adducts including dA-AAI and dG-AAI. dA-AAI, 7-(deoxyadenosin-N6-yl)
aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl) aristolactam I; AAIa, 8-OH-aristolochic acid I
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is known to be involved in activation/detoxification of a
variety of procarcinogens, in the present study, we pre-
treated animal with a non-carcinogen CYP1A inducer
β-naphthoflavone (BNF) to clarify the role of hepatic
CYP1A in the bioactivation of AAI by the detection of
DNA adducts level. We finally determined the effect of
hepatic CYPs on carcinogenesis, induced by AAI. We
demonstrated that hepatic CYPs play a major role in
completing the detoxification cycle and protect the tar-
get organs from AAI-induced genotoxicity.
Materials and methods
Chemicals
AAI (96 %) was obtained from Sigma-Aldrich Co. LLC.
(St. Louis, MO, USA). Aristolactam I (ALI) was obtained
from Shanghai ChemPartner Co. Ltd. (Shanghai, China).
2′-Deoxyadenosine (dA), 2′-deoxyguanosine (dG), DNase
I, and phosphodiesterase I were obtained from Sangon
Biotech Shanghai Co. Ltd. (Shanghai, China). Alkaline
phosphatase was obtained from Sigma-Aldrich Co.
LLC. (St. Louis, MO, USA). HPLC-grade methanol and
acetonitrile were obtained from MSD Sharp & Dohme
Corp. (Munchen, Germany). Other reagents were ana-
lytically pure.
Animal use and treatment
Generation and characterization of HRN gpt delta mice
were reported previously. The Shanghai Animal Care
and Use Committee approved all animal experiments
[Certificate No. SCXK (Shanghai) 2002–0010]. Animals
were acclimatized in specific pathogen-free rooms with
the temperature at 20 to 26 °C, humidity at 30 to 70 %,
and a 12 h light/dark cycle for at least 1 week. Regular
laboratory chow and filtered tap water were allowed, as
per requirements.
AAI-DNA adduct analysis
Wild type (WT) mice were pretreated with a single in-
traperitoneal injection of BNF (BNF-WT) at 80 mg/kg
in corn oil, once daily for 3 days, before injection of
AAI. Male WT, BNF-WT, and HRN gpt mice were intra-
gastically treated with AAI at a dose of 15 mg/kg for
2 days, then killed 24 h following the final treatment, and
kidneys and livers were removed and stored at −40 °C,
until further analysis for AAI-DNA adducts [20].
Mutation assay
Male WT gpt and HRN gpt delta mice, at the age of
8 weeks, were intragastically treated with 15 mg/kg
AAI, once a week, for 4 consecutive weeks. One week
after the final treatment, the mice were killed by cer-
vical dislocation. Kidneys and livers were removed and
quickly frozen in liquid nitrogen, then stored in a deep
freezer at −70 °C until further analysis.
Tumor induction assay
Thirty-nine female WT gpt delta mice and 35 female
HRN gpt delta mice used in this study were divided into
4 groups: WT gpt control, WT gpt-AAI, HRN gpt con-
trol, and HRN gpt delta-AAI. AAI was dissolved in 1 %
NaCO3. Mice were dosed orally with 5 mg/kg AAI for
2 months. Mice were then killed for histological examin-
ation after a 4- and 7-month recovery.
Determination of the levels of AAI and metabolites in
blood, liver, and kidney
Blood samples (20 μl each) were collected by tail bleeding
at 5, 10, 20, 30, 45, 60, 90, 120, 180 min and tissue samples
were collected at 30, 60, 120 and 180 min after a single
oral dose (15 mg/kg) of AAI (n = 4 per group) to male
mice. Collected samples were further processed as de-
scribed previously [21]. Aliquots of the final supernatants
were analyzed and quantified, for the levels of AAI and its
reductive metabolites aristolactam I (ALI) by HPLC. The
identity of AAI and associated metabolites were confirmed
with previously described standards.
Quantitative analysis of AAI–DNA adducts in liver and
kidney of mice
The isolation of total genomic DNA, from kidney and
liver, was carried out by the phenol/chloroform method.
DNA samples were digested and enriched by ethyl
acetate. DNA adducts were detected by the liquid
chromatography-electrospray ionization-multi-stage-mass
spectrometry (LC-ESI-MS–MS) method, reported pre-
viously [23]. Deoxyadenosine-AAI (dA-AAI) (external
standard) and tolbutamide (internal standard) were
used to quantify the concentration of AAI-DNA ad-
ducts, and deoxyadenosine was used to quantify the
concentration of normal deoxynucleosides.
Mutation assay
Mutation assay of gpt gene was performed using the
method, reported previously [22]. Briefly, genomic DNA
was extracted from kidneys and liver, and lambda EG10
DNA (48 kb) was rescued as phages by in vitro pack-
aging. Packaged phages were incubated with Escherichia
coli YG6020. Infected cells were mixed with molten soft
agar and poured onto agar plates containing chloram-
phenicol and 6-Thioguanine (6-TG). To determine the
total number of rescued plasmids, infected cells were
also poured onto plates containing chloramphenicol
without 6-TG. The plates were then incubated at 37 °C.
Positively selected colonies were counted on day 3 and
collected on day 4. The mutant frequencies were calcu-
lated by dividing the number of gpt mutants by the
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number of rescued phages. gpt gene of mutant colonies
were sequenced. Duplicate mutations at the same site
within an individual tissue of gpt gene were excluded to
account for colonial expansion of sibling mutations.
The data obtained from the study were expressed as
mean ± standard deviations. Dunnett’s test, after one-
way ANOVA and Student’s t-test, was used to evaluate
the differences. Mutational spectra were compared
using the computer program written by Cariello [23],
for the Monte Carlo analysis developed by Adams and
Skopek [24]. The calculated p values, which were
lower than 0.05 were considered to indicate statistical
significance.
Tumor induction assay
Mice were killed by an overdose of carbon dioxide
(CO2). After a recovery of 4 or 7 months, the mice were
terminated, and kidney, liver, stomach, small and large
intestine, urinary bladder, lungs, and spleen were ex-
cised and fixed in 10 % formalin for histological exam-
ination. Paraffin sections (3 μm) were prepared and
stained with haematoxylin and eosin, and examined
microscopically.
Results
Levels of AAI and associated metabolites in plasma
and tissues
The contribution of hepatic CYPs to AAI metabolism
was determined in vivo by comparing AAI levels in
blood and tissues between the BNF-pretreated wild-
type (BNF-WT) mice, wild-type gpt delta (WT) mice,
and HRN gpt delta mice. The clearance of AAI was
much slower in HRN gpt delta mice but faster in
BNF-WT mice compared with WT mice (Fig. 2). The
levels of AAI, in the liver and kidney, were deter-
mined at 30 min, 60 min, 120 min, and 180 min after
the dosing of AAI at 15 mg/kg, using LC-MS/MS
analysis. The levels of AAI were higher in HRN gpt
delta mice than that in the WT group in both liver
and kidney, which suggested that inactivation of hepatic
CYPs reduced the clearance of AAI in HRN gpt delta
mice. On the other hand, AAI levels in BNF-WT mice
Fig. 2 The concentrations of AAI in plasma and tissues in BNF-pretreated WT mice, WT mice and HRN gpt delta mice. Upper panel is serum levels
of AAI. Mice were intragastrically treated with AAI at a single dose of 15 mg/kg, tail vein blood samples were collected from individual mice at eight
time points after dosing for determination of AAI concentrations as described in Materials and Methods. Inset: pharmacokinetic variables in mice.
Values presented as mean ± SD, n = 4. *, p < 0.05, **, p < 0.01, compared to WT mice. MRT, Mean Residence Time. Lower is the concentrations of AAI in
the liver and kidney of mice. B-WT, wild-type mice were pretreated with β-naphthoflavone (BNF). WT, wild-type mice. HRN, hepatic Reductase Null gpt
delta mice. #, p < 0.05, ##, p < 0.01, the concentration of AAI in kidney compared to WT mice. *, p < 0.05, **, p < 0.01, the concentration of AAI in liver
compared to WT mice. N = 4
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were lower than in WT mice, suggesting CYP1A may play
a key role in the clearance of AAI.
Formation of AAI-derived DNA adducts in liver
and kidneys
In the detection of AAI-derived DNA adducts, mice were
intragastically treated with AAI at 15 mg/kg for 2 days.
DNA samples of kidney and liver were digested, enriched
by ethyl acetate, and analyzed. Deoxyadenosine-AAI (dA-
AAI) and dG-AAI were determined by the previously de-
veloped method of LC–MS–MS [22], and the response fell
in the linear range between 4 ng/ml to 200 ng/ml. In liver
tissue, AAI-DNA adducts from only HRN gpt delta-AAI
mice can be detected, while BNF-WT-AAI and WT-AAI
mice showed lower levels of adducts, where the response
fell out of the linear range (Table 1). In kidney tissue, the
total amount of AAI-DNA adducts formed in the HRN
gpt delta-AAI mice was higher than those in BNF-WT-
AAI mice and WT-AAI mice (p < 0.05). The DNA adduct
pattern was different in the liver and kidney of HRN gpt
delta-AAI mice, the major DNA adducts in the liver was
dA-AAI, the level was about 1.5-fold higher than that of
dG-AAI, whereas dG-AAI was predominant adducts in
the kidney, showed a 1.5-fold higher level than dA-AAI.
Pretreatment with BNF could reduce the level of AAI-
DNA adducts, which is consistent with the reduction in
the levels of ALI.
Mutant frequencies of gpt induced by AAI in the liver
and kidneys
To calculate the MFs of gpt gene, induced by AAI, we
analyzed 205 500 to 843 000, and 172 500 to 1 027 500
chloramphenicol (Cm)-resistant colonies derived from
the rescued phages of kidneys and liver, respectively. The
frequency of spontaneous mutations in HRN gpt delta-AAI
mice was not significantly different when compared to
control littermates; their values were 5.71 ± 2.71 × 10−6
compared to 2.03 ± 1.78 × 10−6 in the liver, and 4.52 ±
1.37 × 10−6 compared to 2.49 ± 0.74 × 10−6 in the kidneys,
within a historical acceptable range. The MFs of kidney
and liver in HRN gpt delta-AAI mice were 271.96 ±
47.59 × 10−6 and 32.81 ± 32.05 × 10−6, which were 2-fold
and 3-fold higher than those of WT-AAI mice, ie,
121.27 ± 38.48 × 10−6 and 9.26 ± 9.73 × 10−6, respectively
(Fig. 3). We also determined the mutation spectra of
gpt gene in the kidneys and livers of HRN gpt delta-
AAI mice and WT-AAI mice (Additional file 1: Tables
S1, S2). The main mutation was A:T to T:A transver-
sion, whereas G:C to A:T was the dominant mutation
Table 1 Formation of AA-DNA adducts in the liver and kidney




per 107 dN per 107 dN per 107 dN
Liver
B-WT - - -
WT - - -
HRN 15.92 ± 4.46 10.38 ± 4.86 26.29 ± 9.22
Kidney
B-WT 029.94 ± 11.46 24.02 ± 6.30 053.96 ± 16.52
WT 58.09 ± 9.50 68.68 ± 6.93 126.77 ± 12.28*
HRN 101.59 ± 45.30 152.15 ± 26.52 253.75 ± 38.08*
B-WT wild-type mice were pretreated with β-naphthoflavone (BNF); WT wild-type
mice, HRN hepatic Reductase Null gpt delta mice
Values presented are mean ± SD, n = 5, dN, deoxynucleosides.*, p < 0.05
compare with WT mice. -, not detected
Fig. 3 Mutant frequencies of gpt induced by AAI in the kidney and
liver of mice. Eight-week-old, male, WT and HRN gpt delta mice were
administrated AAI once a week for 4 weeks. One week after the last
dose, the mice were euthanized. The liver and kidney were taken
and quickly frozen in liquid nitrogen, then kept in freezer at −70 °C
until being analyzed. a, the mutant frequencies of gpt gene in the
kidney of mice. The mutant frequencies of gpt in kidney for WT
Control, HRN gpt delta Control, WT-AAI and HRN-AAI were 2.49 ±
0.74 × 10−6, 4.52-1.37 × 10−6, 121.27 ± 38.48 × 10−6 and 271.96 ±
47.59 × 10−6 respectively. b, the mutant frequencies of gpt in the
liver of mice. The mutant frequencies of gpt in liver for WT Control,
HRN Control, WT-AAI and HRN-AAI were 2.03 ± 1.78 × 10−6, 5.71 ±
2.71 × 10−6, 9.26 ± 9.73 × 10−6 and 32.81 ± 32.05 × 10−6 respectively.
Values presented are the mean ± SD, N = 5
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in the untreated mice (p > 0.05), which was consistent
with the current understanding of AAI-induced muta-
genesis and reported data.
Preneoplasia and neoplasia induced by AAI
To elucidate the contribution of hepatic CYPs to AAI
induced carcinogenesis, tumor induction was deter-
mined following exposure to AAI at 5 mg/kg/day for
2 months. The survival rates of WT gpt-AAI mice and
HRN gpt delta-AAI mice were 62.5 % (5/8) and 80.0 %
(8/10) for recovery in 4 months, and 47.1 (8/17) and
42.1 % (8/19) for recovery in 7 months, respectively,
whereas the survival rate of control groups (WT gpt and
HRN gpt) was 100 %. No significant difference, in sur-
vival rate, was found between WT gpt-AAI and HRN gpt
delta-AAI mice. All neoplastic findings are shown nu-
merically in Table 2. After treatment for 2 months and
recovery of 4 months, the squamous epithelium showed
marked hyperplasia and hyperkeratosis in both WT gpt-
AAI and HRN gpt delta-AAI mice. Papillomatous
changes occurred in the forestomach in both WT gpt-
AAI and HRN gpt delta-AAI mice (Table 2). Most papil-
lomas, observed at some points, were coneshaped and
bulging out of the epithelium against the submucosa
without penetrating the muscularis mucosae, except one
HRN gpt delta-AAI mouse, where the papilloma pene-
trated through the muscularis mucosae (1/8) (Fig. 4b).
Papillomas with vacuolated cytoplasm, irregular nuclei,
and numerous mitoses, mainly atypical forms were
found in one WT gpt-AAI mouse (Fig. 4a). After recov-
ery of 7 months, papilloma with signs of malignancy and
penetration through muscularis mucosae or presentation
of irregular nuclei were found in 2 WT gpt-AAI mice
(2/8) and one HRN gpt delta-AAI mouse (1/8). Squa-
mous cell carcinomas were found in 1 WT gpt-AAI
mouse (1/8), which was within the stomach. Squamous
cell carcinomas were found in 2 HRN gpt delta-AAI
mice (2/8), which had penetrated through the stomach
to invade the esophagus, glandular stomach, and other
surrounding tissues (Fig. 4c), and 1 metastasis was
present in the liver had invaded the esophagus (Fig. 4e).
Histologically, tumors were identified as keratinized squa-
mous cell carcinomas with epithelial pearl formation,
irregular nuclei, and disappearance of normal tissue struc-
ture. Adenoma was found in the duodenum in 2 other
HRN gpt delta-AAI mice (2/8) treated with AAI, in the
absence of squamous cell carcinomas, after recovery of
7 months (Fig. 4d). No preneoplastic or neoplastic
changes were detected in the control animals (WT gpt
and HRN gpt) in either histological or macroscopic exami-
nations. Karyomegaly, peritubular fibrosis, and basophilic
atypical tubules were present in the kidneys of HRN/WT
gpt delta mice, treated with AAI, after recovery of 4 and
7 months.
Discussion
As several studies indicate, metabolism of AAI plays a
very important role in the initiation and progress of aris-
tolochic acid nephropathy (AAN) and Balkan endemic
nephropathy (BEN) [19, 26–29]. Understanding which
enzymes are involved in AAI activation and/or detoxifi-
cation is important in the assessment of the susceptibil-
ity to this carcinogen. AAI could be demethylated to
form AAIa, excreted individually or conjugated with glu-
curonide, acetate, or sulfate esters, which is the meta-
bolic detoxification pathway of AAI. Human and rodent
enzymes, CYP1A1 and CYP1A2, are the principal en-
zymes involved in the detoxification pathway in vitro
and in vivo. AAI could also be activated by nitroreduc-
tion metabolism and generate an intermediate a cyclic
nitrenium ion, which can covalently bind the exocyclic
amino groups of DNA bases, NAD(P)H:quinone oxido-
reductase (NQO1). CYP1A1 and CYP1A2 have been
proven to be the main responsive enzymes, in vitro and
in vivo [16–18]. Therefore, CYPs are involved in both
detoxification and reductive activation of AAI. The
present study has been designed to obtain an overall
evaluation of the role of hepatic CYPs in the contrasting
processes of detoxification or activation of AAI by meas-
uring 3 toxic endpoints: DNA adduct formation, gene
mutation, and tumor induction by using a novel HRN
gpt delta mouse model.
In the present study, the levels of AAI, in blood, kid-
ney, and liver, in HRN gpt delta-AAI mice were higher
than those in BNF-WT-AAI mice and WT-AAI mice.
The number of AAI-DNA adducts formed in the kidney
Table 2 Number of neoplsia in WT mice and HRN gpt delta mice treated with AAI for two months
Organ Tumor 4 months recovery 7 months recovery
Con WT HRN Con WT HRN
Forestomach Papilloma with signs of malignancy 0 1 1 2 1
Squamouse cell carcinoma 0 0 0 1 2
Duodenum Adenoma 0 0 0 0 2
Mice with neoplasia 0/10 1/8 1/5 0/10 3/8 5/8
WT wild-type mice; HRN hepatic Reductase Null gpt delta mice
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and liver of HRN gpt delta-AAI mice were also higher
than those in BNF-WT-AAI mice and WT-AAI mice.
These results suggested that hepatic CYPs metabolize
AAI, and reduce the exposure level and formation of
AAI-DNA adducts in vivo, which were consistent with
the results reported previously [21, 30]. We further deter-
mined the gpt mutant frequencies, mutation spectrum,
and tumor induction to study the effects of hepatic CYPs
on AAI-induced mutagenesis and tumorigenesis by using
the HRN gpt delta-AAI mice. Our findings provide further
substantial evidence that the main role of hepatic CYPs is
to help AAI to be excreted, and to protect target organs
against AAI-induced mutagenesis and tumorigenesis.
We previously reported HRN gpt delta mice could
provide useful information on the metabolism of car-
cinogen [15]. It is indisputable that a direct measure of
induced gene mutations is better than other genetic end
points such as DNA damage. The formation of DNA ad-
ducts is a critical determinant of mutagenicity, however,
the final mutational events depend also on DNA repair
which can eliminate DNA adducts. In the present study,
our data showed the level of dG-AAI was higher than
dA-AAI in the kidney of AAI treated HRN-gpt mice, but
the dominant mutation pattern was at A:T- > T:A in the
kidney of AAI treated HRN-gpt mice (Additional file 1:
Table S1), suggested the DNA repair efficiency might be
different between dA-AAI and dG-AAI, which need a
further study. Moreover, metabolic activation usually
generates various intermediates from different pathways,
which may pose difficulties for detection of DNA ad-
ducts, although our in vivo gene mutation assay will
overcome this limitation. Furthermore, HRN gpt delta
Fig. 4 Histopathological features of neoplastic changes in WT gpt and HRN gpt delta mice induced by AAI. a, the papilloma with vacuolated
cytoplasm, irregular nuclei and numerous mitoses, mainly atypical forms was found in one WT gpt mouse (HE × 400). b, the papilloma penetrated
through muscularis mucosae found in forestomach of one HRN gpt mouse(HE × 200). c, Squamouse cell carcinoma was found in one HRN gpt
delta mouse which had penetrated through stomach to invade esophagus (HE × 100). d, Adenoma was found in one HRN gpt delta mouse
without squamous cell carcinomas (HE × 200). e, a metastasis was present in the liver of one HRN gpt delta mouse in which squamouse cell
carcinoma had invaded into esophagus (HE × 500)
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mice could detect deletion mutations by Spi- assay. The
Spi- assay results showed that HRN gpt delta mice had
higher MFs than WT mice, but the magnitude of in-
crease for Spi- assay was lower than that of 6-TG selec-
tion (Additional file 1: Figure S1). Mutation spectrum
analysis showed the predominant deletion was 1 to 2
base pairs, which occurred in “C” or “G” bases in gam
gene (Additional file 1: Table S3), which was different
from 6-TG selection. The mechanism of mutagenesis
thus, needs to be further investigated.
Carcinogenic profiles are different between rats and
mice dosing with AA in varied recipes [25, 31–33]. The
papillomas and squamous cell carcinomas in foresto-
mach and urinary bladder, adenomas, mesenchymal tu-
mours and oncocytoma in kidney, carcinomas in renal
pelvis et al. could be found in rats [31–33], whereas pap-
illomas and squamous cell carcinomas in forestomach,
carcinomas in lung, adenomas in kidney et al. could be
found in miceafter administration of different doses of
AA or AAI in different dosing durations [25]. The re-
sults indicated that the main carcinogenic profiles up to
date for the mice are the papillomas and squamous cell
carcinomas occurred in forestomach, the carcinomas in
lung and the adenomas in kidney.
It was reported that the short-term high dose AA or
AAI exposure could induce cancers and tumors in both
rats and mice though the profile were somehow differ-
ent. Mengs [25] found papillomatous changes occurred
in the forestomach, squamous cell carcinomas were ob-
served in all the animals, adenomas of the kidneys, car-
cinomas of the lungs, and haemangiomas of the uteri
after treatment for 3 weeks with AA in daily doses of
5.0 mg/kg in NMRI mice which were kept under obser-
vation for approximately 1 year. Another study reported
by Cui et al. [33] showed female Sprague–Dawley rats
dosed with AAI at 50 mg/kg for consecutive three days
could induce tumors in kidney. Based on this specula-
tion, the dose at 5 mg/kg AAI was selected for our
study and the dosing duration was also prolonged to
2 months (nearly 8 weeks) which was longer than
Mengs’ study and was supposed to induce tumors or
cancers earlier. The total durations for determining the
tumorigenesis or carcinogenesis were 6 months and
9 months after the first administration which equiva-
lent to the durations of 26 weeks and 37 weeks re-
ported by Mengs [25]. Due to the high tumor incidence
found in the Mengs’ study, the minimum group size
should be ≥ 4. We aimed to obtain the comparable data
between AAI-gpt and AAI-HRN-gpt to investigate if
there were differences between them. The papilloma
and squamous cell carcinomas were present in the forest-
omach in both, AAI-gpt and AAI-HRN-gpt mice. We
found adenomas in the duodenum in 2 other AAI-HRN-
gpt mice in the absence of squamous cell carcinomas.
One squamous cell carcinoma was present in the liver of
one HRN mouse, and had invaded the esophagus. The
results indicated that the AAI-HRN-gpt mice showed
a higher sensitivity for AAI tumorigenesis or the when
CYPs activity is reduced in liver more tumors and of
higher severity are induced in the extra-hepatic target
tissues.
Conclusion
By using HRN gpt delta mice, we demonstrated that al-
though hepatic CYPs are involved in AAI-induced mu-
tagenicity, the main role of CYPs is to help AAI to be
excreted, and to protect target organs against AAI-induced
DNA adduct formation, mutagenesis, and tumorigenesis.
Additional file
Additional file 1: Figure S1. Spi- mutant frequencies of deletions
induced by AAI in the kidney and liver of mice. Eight-week-old, male, WT
and HRN gpt delta mice were administrated AAI once a week for 4 weeks.
One week after the last dose, the mice were euthanized. The liver and
kidney were taken and quickly frozen in liquid nitrogen, then kept in
freezer at -70oC until being analyzed. Table S1 Summary of independent
mutations in the gpt gene of kidney from AAI treated and control mice.
Table S2 Summary of independent mutations in the gpt gene of liver
from AAI treated and control mice. Table S3 Summary of Spi- deletions
in WT and HRN mice induced by AAI.
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